Secondary failure rates of measles vaccines: A metaanalysis of published studies

Jennifer F Anders, Robert M. Jacobson, Gregory A. Poland, Steven J. Jacobsen, Peter C. Wollan

Research output: Contribution to journalArticle

Abstract

Background. Recent measles outbreaks in highly vaccinated populations have highlighted the role of vaccine failure as a barrier to the elimination of measles. We sought to estimate the rate of secondary failure (clinical measles after vaccine-induced seroconversion) of measles vaccines using metaanalysis. Methods. We identified 1411 studies of which 125 were relevant. From these we found 10 original studies of healthy subjects with sufficient details to calculate a pooled secondary failure rate. We performed a test for homogeneity before any pooling. Results. Although significant heterogeneity prevented their pooling as a single group, the studies fell into three homogeneous groups suitable for pooling. Group A studies used killed vaccine whereas the other two groups (Groups B and C) of studies used live vaccine. These latter groups differ in that the studies in Group B share higher failure rates and are difficult to interpret with respect to the lack of verification of vaccination, immunization before 12 months of age and a non- North American study site and vaccine manufacturer. Those studies in Group C, in which US subjects were older than 12 months at vaccination and received a live US-manufactured vaccine that was documented in a medical record, had a failure rate of 0 of 2031 with a 95% confidence interval of 0.0 to 0.147%. Conclusions. Although reports of measles related to secondary failure exist, studies that permit the calculation of the rate of secondary failure demonstrate that the rate appears to be

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalPediatric Infectious Disease Journal
Volume15
Issue number1
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Measles Vaccine
Measles
Vaccines
Vaccination
Inactivated Vaccines
Medical Records
Disease Outbreaks
Immunization
Healthy Volunteers
Confidence Intervals
Population

Keywords

  • immunization
  • Measles
  • metaanalysis
  • vaccine
  • vaccine failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Secondary failure rates of measles vaccines : A metaanalysis of published studies. / Anders, Jennifer F; Jacobson, Robert M.; Poland, Gregory A.; Jacobsen, Steven J.; Wollan, Peter C.

In: Pediatric Infectious Disease Journal, Vol. 15, No. 1, 1996, p. 62-66.

Research output: Contribution to journalArticle

Anders, Jennifer F ; Jacobson, Robert M. ; Poland, Gregory A. ; Jacobsen, Steven J. ; Wollan, Peter C. / Secondary failure rates of measles vaccines : A metaanalysis of published studies. In: Pediatric Infectious Disease Journal. 1996 ; Vol. 15, No. 1. pp. 62-66.
@article{ef9210d152db4b2b8660bacf98000768,
title = "Secondary failure rates of measles vaccines: A metaanalysis of published studies",
abstract = "Background. Recent measles outbreaks in highly vaccinated populations have highlighted the role of vaccine failure as a barrier to the elimination of measles. We sought to estimate the rate of secondary failure (clinical measles after vaccine-induced seroconversion) of measles vaccines using metaanalysis. Methods. We identified 1411 studies of which 125 were relevant. From these we found 10 original studies of healthy subjects with sufficient details to calculate a pooled secondary failure rate. We performed a test for homogeneity before any pooling. Results. Although significant heterogeneity prevented their pooling as a single group, the studies fell into three homogeneous groups suitable for pooling. Group A studies used killed vaccine whereas the other two groups (Groups B and C) of studies used live vaccine. These latter groups differ in that the studies in Group B share higher failure rates and are difficult to interpret with respect to the lack of verification of vaccination, immunization before 12 months of age and a non- North American study site and vaccine manufacturer. Those studies in Group C, in which US subjects were older than 12 months at vaccination and received a live US-manufactured vaccine that was documented in a medical record, had a failure rate of 0 of 2031 with a 95{\%} confidence interval of 0.0 to 0.147{\%}. Conclusions. Although reports of measles related to secondary failure exist, studies that permit the calculation of the rate of secondary failure demonstrate that the rate appears to be",
keywords = "immunization, Measles, metaanalysis, vaccine, vaccine failure",
author = "Anders, {Jennifer F} and Jacobson, {Robert M.} and Poland, {Gregory A.} and Jacobsen, {Steven J.} and Wollan, {Peter C.}",
year = "1996",
doi = "10.1097/00006454-199601000-00014",
language = "English (US)",
volume = "15",
pages = "62--66",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Secondary failure rates of measles vaccines

T2 - A metaanalysis of published studies

AU - Anders, Jennifer F

AU - Jacobson, Robert M.

AU - Poland, Gregory A.

AU - Jacobsen, Steven J.

AU - Wollan, Peter C.

PY - 1996

Y1 - 1996

N2 - Background. Recent measles outbreaks in highly vaccinated populations have highlighted the role of vaccine failure as a barrier to the elimination of measles. We sought to estimate the rate of secondary failure (clinical measles after vaccine-induced seroconversion) of measles vaccines using metaanalysis. Methods. We identified 1411 studies of which 125 were relevant. From these we found 10 original studies of healthy subjects with sufficient details to calculate a pooled secondary failure rate. We performed a test for homogeneity before any pooling. Results. Although significant heterogeneity prevented their pooling as a single group, the studies fell into three homogeneous groups suitable for pooling. Group A studies used killed vaccine whereas the other two groups (Groups B and C) of studies used live vaccine. These latter groups differ in that the studies in Group B share higher failure rates and are difficult to interpret with respect to the lack of verification of vaccination, immunization before 12 months of age and a non- North American study site and vaccine manufacturer. Those studies in Group C, in which US subjects were older than 12 months at vaccination and received a live US-manufactured vaccine that was documented in a medical record, had a failure rate of 0 of 2031 with a 95% confidence interval of 0.0 to 0.147%. Conclusions. Although reports of measles related to secondary failure exist, studies that permit the calculation of the rate of secondary failure demonstrate that the rate appears to be

AB - Background. Recent measles outbreaks in highly vaccinated populations have highlighted the role of vaccine failure as a barrier to the elimination of measles. We sought to estimate the rate of secondary failure (clinical measles after vaccine-induced seroconversion) of measles vaccines using metaanalysis. Methods. We identified 1411 studies of which 125 were relevant. From these we found 10 original studies of healthy subjects with sufficient details to calculate a pooled secondary failure rate. We performed a test for homogeneity before any pooling. Results. Although significant heterogeneity prevented their pooling as a single group, the studies fell into three homogeneous groups suitable for pooling. Group A studies used killed vaccine whereas the other two groups (Groups B and C) of studies used live vaccine. These latter groups differ in that the studies in Group B share higher failure rates and are difficult to interpret with respect to the lack of verification of vaccination, immunization before 12 months of age and a non- North American study site and vaccine manufacturer. Those studies in Group C, in which US subjects were older than 12 months at vaccination and received a live US-manufactured vaccine that was documented in a medical record, had a failure rate of 0 of 2031 with a 95% confidence interval of 0.0 to 0.147%. Conclusions. Although reports of measles related to secondary failure exist, studies that permit the calculation of the rate of secondary failure demonstrate that the rate appears to be

KW - immunization

KW - Measles

KW - metaanalysis

KW - vaccine

KW - vaccine failure

UR - http://www.scopus.com/inward/record.url?scp=0030048783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030048783&partnerID=8YFLogxK

U2 - 10.1097/00006454-199601000-00014

DO - 10.1097/00006454-199601000-00014

M3 - Article

C2 - 8684879

AN - SCOPUS:0030048783

VL - 15

SP - 62

EP - 66

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 1

ER -